LOGO.jpg
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
14 nov. 2023 07h30 HE | QSAM Biosciences Inc.
Austin, TX, Nov. 14, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing therapeutic radiopharmaceuticals for the treatment of primary and secondary bone cancer and...
LOGO.jpg
QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
16 août 2023 08h00 HE | QSAM Biosciences Inc.
AUSTIN, Texas, Aug. 16, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
22157.jpg
Global Interventional Oncology Devices Market Report 2023: Players Include Boston Scientific, Medtronic, Terumo, and Philips Volcano
30 mars 2023 10h18 HE | Research and Markets
Dublin, March 30, 2023 (GLOBE NEWSWIRE) -- The "Interventional Oncology Devices Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides...
AMR Logo.png
Artificial Tendons and Ligaments Market Is Expected to Reach $165.7 Million by 2031: Says AMR
14 déc. 2022 03h59 HE | Allied Market Research
Portland, OR, Dec. 14, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Artificial Tendons And Ligaments Market was estimated at $64.3 million in 2021...
LOGO.jpg
QSAM Biosciences Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer
26 oct. 2022 08h00 HE | QSAM Biosciences Inc.
Austin, TX, Oct. 26, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
AMR Logo.png
Global Bone Cancer Treatment Market to Reach $1.8 Billion by 2031: Says AMR
21 oct. 2022 08h51 HE | Allied Market Research
Portland, OR, Oct. 21, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Bone Cancer Treatment Market was estimated at $1.2 billion in 2021 and is...
LOGO.jpg
QSAM Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
16 août 2022 08h00 HE | QSAM Biosciences Inc.
Progress Shown in Phase 1 Clinical Program Evaluating CycloSam® Radiopharmaceutical Drug Candidate for Treatment of Metastatic Bone Cancer AUSTIN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- QSAM...
Featured Image for Hospital At Home
Hospital at Home Program Helping Cancer Patients and Their Families With Medical and Financial Support Services
29 juin 2022 16h00 HE | Hospital At Home
CALGARY, Alberta, June 29, 2022 (GLOBE NEWSWIRE) -- As a competitive dancer and avid horseback rider, Lauren Gamble's life changed completely on Aug. 13, 2021. Lauren received an osteosarcoma...
LOGO.jpg
QSAM Biosciences Activates Clinical Sites and Opens Enrollment for its Phase 1 Clinical Trial of CycloSam® for the Treatment of Bone Cancer
01 déc. 2021 09h00 HE | QSAM Biosciences Inc.
Austin, TX, Dec. 01, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
22157.jpg
Global $3.32 Bn Interventional Oncology Devices Market to 2030: Embolization Devices, Ablation Devices, & Support Devices
16 juil. 2021 05h53 HE | Research and Markets
Dublin, July 16, 2021 (GLOBE NEWSWIRE) -- The "Interventional Oncology Devices Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's...